Current stage-Stage IV Posts on Medivizor

Comparing the effectiveness and safety of chemotherapy-based combination therapies as first-line treatment for advanced non-small cell lung cancer with negative PD-L1.

Posted by Medivizor on Oct 22, 2023 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety of chemotherapy-based combination therapies for the treatment of patients with advanced non-small cell lung cancer (NSCLC) with negative PD-L1 expression. The data showed that pembrolizumab (Keytruda) plus chemotherapy combination was the best treatment regimen for improving overall survival...

How useful is thoracic tumor radiation in improving overall survival of patients with non-small-cell lung cancer and malignant pleural effusion?

Posted by Medivizor on Sep 17, 2023 in Lung cancer | 0 comments

In a nutshell This study investigated the effect of thoracic tumor radiotherapy on overall survival (OS) in patients with metastatic non-small-cell lung cancer (NSCLC) with malignant pleural effusion (MPE). The authors concluded that thoracic tumor radiotherapy effectively improved OS with acceptable toxicity levels in these patients. Some background...

Comparing the long-term effectiveness and safety of trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer

Posted by Medivizor on Jun 11, 2023 in Breast cancer | 0 comments

In a nutshell The study compared the effectiveness and safety of trastuzumab deruxtecan (TD; Enhertu) with trastuzumab emtansine (TE; Kadcyla) in patients with HER2-positive (HER2+) metastatic breast cancer (BC). The study found that TD was more effective and well-tolerated compared to TE in these patients. Some background HER2+ BC...

Comparing the effectiveness of TAS-102 versus regorafenib for the treatment of patients with metastatic colorectal cancer.

Posted by Medivizor on Dec 9, 2022 in Colorectal cancer | 0 comments

In a nutshell This study compared the effectiveness of TAS-102 (Lonsurf; trifluridine-tipiracil) versus regorafenib (Stivarga) for the treatment of patients with metastatic colorectal cancer (mCRC). The data showed that TAS-102 had better oncologic outcomes than regorafenib in these patients. Some background Colorectal cancer (CRC) is one of the...

Comparing the effectiveness and safety of combined therapy of pertuzumab with trastuzumab versus single trastuzumab therapy in patients with HER2-positive advanced breast cancer

Posted by Medivizor on Nov 14, 2022 in Breast cancer | 0 comments

In a nutshell The study compared the effectiveness and safety of pertuzumab (Perjeta) and trastuzumab (Herceptin) combined therapy with trastuzumab alone in patients with HER2-positive (HER2+) advanced breast cancer (BC). The study found that the combined therapy was more effective and well tolerated compared to single therapy in...

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

Posted by Medivizor on Nov 7, 2021 in Breast cancer | 0 comments

In a nutshell This study investigated the side effect profiles of different PD-1/PD-L1 inhibitor-based combination therapies. The data showed that PD-1/PD-L1 inhibitors in combination with chemotherapy were associated with a higher risk of treatment-related side effects than with targeted therapy or immunotherapy combinations. Some background...

Comparing the effectiveness and safety of nivolumab plus ipilimumab with chemotherapy versus pembrolizumab plus chemotherapy as first-Line treatment for metastatic NSCLC.

Posted by Medivizor on Oct 17, 2021 in Lung cancer | 0 comments

In a nutshell This study compared the effectiveness and safety outcomes of nivolumab (N; Opdivo) plus ipilimumab (I; Yervoy) with chemotherapy versus pembrolizumab (Pem; Keytruda) plus chemotherapy as first-line treatment in patients with metastatic non-small cell lung cancer (NSCLC). The data showed that N-I plus chemotherapy provided similar overall...

Comparing PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer.

Posted by Medivizor on May 30, 2021 in Lung cancer | 0 comments

In a nutshell This study investigated the effectiveness and safety outcomes of programmed death-1 (PD-1)/PD ligand 1 (PD-L1) inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer (NSCLC). The data showed that PD-1/PD-L1 inhibitors were safer and more effective than chemotherapy in these patients. Some...

Irinotecan plus bevacizumab improves metastatic colorectal cancer outcomes

Posted by Medivizor on May 23, 2021 in Colorectal cancer | 0 comments

In a nutshell This study investigated the best first-line therapy to add to bevacizumab (Avastin) treatment in patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC). Researchers suggested that irinotecan (Camptosar) plus bevacizumab improved the outcomes of these patients. Some background Colorectal cancer is...

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Posted by Medivizor on Apr 30, 2021 in Melanoma | 0 comments

In a nutshell This study is searching for participants with advanced solid tumors including melanoma to examine the safety and effectiveness of experimental drug avapritinib (Ayvakit). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Posted by Medivizor on Apr 30, 2021 in Lung cancer | 0 comments

In a nutshell This study is searching for participants with advanced solid tumors including lung cancer to examine the safety and effectiveness of experimental drug avapritinib (AYVAKIT). The main outcomes to be measured are the response to treatment and side effects. This trial is being conducted in Texas, US. The details Some cancers grow as a...

Comparing the safety and effectiveness of pyrotinib versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer

Posted by Medivizor on Apr 18, 2021 in Breast cancer | 0 comments

In a nutshell This study compared the safety and effectiveness of pyrotinib (SHR-1258) plus capecitabine (Xeloda) versus lapatinib (Tyverb) plus capecitabine in patients with metastatic human epidermal growth factor (HER2)-positive breast cancer (BC) after previous treatment with trastuzumab (Herceptin) and chemotherapy. The data...

Current stage-Stage IV Posts on Medivizor

Comparing the effectiveness and safety of chemotherapy-based combination therapies as first-line treatment for advanced non-small cell lung cancer with negative PD-L1.

How useful is thoracic tumor radiation in improving overall survival of patients with non-small-cell lung cancer and malignant pleural effusion?

Comparing the long-term effectiveness and safety of trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer

Comparing the effectiveness of TAS-102 versus regorafenib for the treatment of patients with metastatic colorectal cancer.

Comparing the effectiveness and safety of combined therapy of pertuzumab with trastuzumab versus single trastuzumab therapy in patients with HER2-positive advanced breast cancer

Investigating the side effect profiles of different PD-L1/PD-1 inhibitor-based combination therapies.

Comparing the effectiveness and safety of nivolumab plus ipilimumab with chemotherapy versus pembrolizumab plus chemotherapy as first-Line treatment for metastatic NSCLC.

Comparing PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer.

Irinotecan plus bevacizumab improves metastatic colorectal cancer outcomes

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Searching for patients with solid tumors with abnormal genetic changes to trial an experimental medication

Comparing the safety and effectiveness of pyrotinib versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer

Categories

Recent Posts

Archives

Current stage-Stage IV Posts on Medivizor

Categories

Recent Posts

Archives

Thanks for your interest in Medivizor

Invalid email